Since receiving global regulatory approval under the brand name Yeztugo®, twice-yearly injectable Lenacapavir has transformed HIV prevention. By offering nearly 100% protection against HIV-1 with just one clinic visit every six months, it eliminates the need for daily pills.
However, for anyone considering switching from daily oral tablets to a twice-yearly shot, one practical question comes first: What is the Lenacapavir price in India, and when will affordable Indian generics be available at your clinic?
Here is a complete breakdown of Lenacapavir’s global pricing, India’s landmark generic manufacturing partnerships, expected local costs, and how you can access long-acting HIV prevention through Lenacapavir for PrEP in India at HIV Care India.
Quick Summary: Key Takeaways on Lenacapavir Cost in India
- Global Branded Price vs. Indian Generic Price: While branded Yeztugo® carries a US list price of over $28,000 (~₹23.5 Lakhs) per year, India is covered under Gilead Sciences' voluntary licensing agreements for low- and middle-income countries (LMICs).
- Landmark $40/Year (~₹3,400/Year) Agreements: Indian pharmaceutical giants Dr. Reddy’s Laboratories and Hetero Labs have partnered with global health organizations (Unitaid, CHAI, and the Gates Foundation) to supply generic twice-yearly Lenacapavir at an estimated target benchmark of $40 per person per year starting in 2027.
Why Is There Such a Massive Gap Between US and Indian Prices?
When Gilead Sciences launched Yeztugo® (lenacapavir) for Pre-Exposure Prophylaxis (PrEP) in the United States, the annual wholesale acquisition cost was set at $28,218 per year. Earlier, when the same molecule was approved as Sunlenca® for multi-drug resistant HIV treatment, prices exceeded $42,000 annually.
Fortunately, patients in India will not pay Western branded prices.
India is the backbone of global antiretroviral manufacturing. To ensure equitable access across 120 high-incidence, resource-limited nations, Gilead signed royalty-free Voluntary Licensing (VL) agreements with six generic manufacturers—four of which have major manufacturing hubs in India:
Dr. Reddy’s Laboratories
Hetero Labs
Emcure Pharmaceuticals
Mylan (a Viatris company)
Because these Indian pharmaceutical leaders receive direct technology transfers and pay zero royalties to Gilead, they can manufacture exact bioequivalent versions of the 6-month injection at a fraction of the international cost.
- Beware of Unverified Online Listings: Do not purchase unverified vials advertised on third-party B2B marketplaces. Lenacapavir requires strict medical screening and clinic-administered subcutaneous injections.
Expected Generic Lenacapavir Price in India (2026–2027 Outlook)
In a historic breakthrough for HIV prevention, global health partnerships have established a clear pricing benchmark for generic Lenacapavir manufactured in India:
Public & Access Program Benchmark (~₹3,400 / $40 per year): Through landmark agreements between Dr. Reddy’s Laboratories (with Unitaid, the Clinton Health Access Initiative [CHAI], and Wits RHI) and Hetero Labs (with the Gates Foundation), generic twice-yearly Lenacapavir is set to be produced at approximately US $40 per person per year (around ₹3,350 to ₹3,500 annually for both 6-month doses, including the oral initiation tablets) as commercial scale-up rolls out in 2027.
Private Clinic & Retail Pricing in India: While the $40/year figure represents high-volume institutional procurement for public health programs across 120 LMICs, private healthcare MRP in India typically includes cold-chain/storage logistics, GST, baseline HIV-1 RNA viral load screening, and clinical administration fees. Even in private specialist clinics, Indian generic Lenacapavir is projected to be priced competitively alongside annual spending on daily oral PrEP.
⚠️ Warning: Avoid Unverified Gray-Market Online Listings
If you search for "Lenacapavir injection price in India" on B2B directories or online marketplaces today, you may see unverified third-party traders listing imported or unapproved vials anywhere from ₹3,000 to ₹75,000. Do not purchase injectable PrEP from unverified online sellers.
Counterfeit & Storage Risks: Improperly stored or counterfeit vials offer zero protection against HIV.
Risk of Drug Resistance: Taking Lenacapavir without a confirmed negative 4th-Generation HIV test and HIV-1 RNA test can cause severe drug resistance if you have an undiagnosed early HIV infection.
Professional Administration Required: Lenacapavir must be injected subcutaneously into the abdomen by a trained healthcare provider alongside a specific oral tablet lead-in schedule.
How to Protect Yourself Right Now: "Bridging" to Lenacapavir at HIV Care India
You do not need to wait for generic injectable stock to reach your local pharmacy to be 99% protected against HIV today. At HIV Care India, our infectious disease specialists use a seamless PrEP Bridging .
Keywords
